This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=69 http://www.lsis.com/goto/r69/rss 2012-05-21T11:10:45+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 March 2011 - Achieving 25 years at the forefront of Molecular Biology is a significant milestone for Cambio, a leading supplier of reagents and consumables for research. The company s constant focus on the future continues with the addition of new products designed for Next Generation DNA and RNA sequencing. One of Cambio s main suppliers is EPICENTRE Biotechnologies, founded in 1987 and based in Madison, Wisconsin. As the exclusive UK distributor, Cambio provides EPICENTRE kits and reagents (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/channels/?query=69 NEW YORK, Nov. 30 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Gene Therapy - Worldwide Market Challenges & Opportunities http:/www.reportlinker.com/p0164218/Gene-Therapy-Worldwide-Market-Challenges-Opportunities.html Gene therapy promises to be one of the most important frontiers in medicine. Although no significant achievements for curing disease have been achieved, the future seems to hold significant potential in terms of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Existing methods for site-directed plasmid mutagenesis are restrained by the small spectrum of modifications that can be introduced by mutagenic primers and the amplicon size limitations of in vitro DNA synthesis. As demonstrated here, the combined use of Red/ET recombination and unique restriction site elimination enables extensive manipulation regardless of plasmid size and DNA sequence elements. First, a selectable marker is PCR-amplified with synthetic primers attaching 50-bp homology (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=69 02.06.2009 - Gene Bridges GmbH announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method", is a method for generating targeting vectors or modifying E. coli chromosomes. "Red/ET is fast becoming the standard DNA engineering technology (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method, is a valued method for generating targeting vectors or modifying E. coli chromosomes. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges. text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=69 27.03.2009 - Gene Bridges GmbH announced that Daiichi Sankyo Co., Ltd. has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method", is a valued method for generating targeting vectors or modifying E. coli chromosomes. "We are very pleased to welcome another major Japanese pharmaceutical company as a licensee of Red/ET, commented Gary Stevens, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Daiichi Sankyo Co., Ltd. of Tokyo, Japan has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. World Biotechnology Reagents Market http:/www.reportlinker.com/p098414/World-Biotechnology-Reagents-Market.html This report analyzes the worldwide markets for Biotechnology Reagents in Millions of US$. The specific product segments analyzed are Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis Reagents, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. World Gene Therapy Market http:/www.reportlinker.com/p098244/World-Gene-Therapy-Market.html This report analyzes the world market for Gene Therapy in Millions of US$. Annual forecasts are provided for the global market for the period of 2007 through 2015. The report profiles 100 companies including many key and niche (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Syncytin-2 is an envelope gene from the human endogenous retrovirus FRD (HERV-FRD) co-opted by an ancestral primate host, conserved in evolution over 40 Myr, specifically expressed in the placenta, and with a cell-cell fusogenic activity likely contributing to placenta morphogenesis. Here, using the GeneBridge4 human/Chinese hamster radiation hybrid panel, we mapped and identified the human receptor for syncytin-2. This receptor-namely Major Facilitator Superfamily Domain Containing 2 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Takeda Pharmaceutical Company Limited of Osaka, Japan has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method , is a valued method for generating targeting vectors or modifying E. coli chromosomes. Gary Stevens, CEO of Gene Bridges (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Takeda Pharmaceutical Company Limited of Osaka, Japan has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 System-oriented applications of genetic engineering, such as metabolic engineering, often require the serial optimization of enzymatic reaction steps, which can be achieved by transcriptional fine-tuning. However, approaches to changing gene expression are usually limited to deletion and/or strong overexpression and rarely match the desired optimal transcript levels. A solution to this all-or-nothing approach has been the use of a synthetic promoter library (SPL) that is based on randomized (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Horizontal gene transfer by transposition has been widely used for transgenesis in prokaryotes. However, conjugation has been preferred for transfer of large transgenes, despite greater restrictions of host range. We examine the possibility that transposons can be used to deliver large transgenes to heterologous hosts. This possibility is particularly relevant to the expression of large secondary metabolite gene clusters in various heterologous hosts. Recently, we showed that the engineering (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=69 01 Aug 2008 - Gene Bridges GmbH announced that it has been granted patents in Japan and in Mexico relating to the Company's recombineering technology. The Japanese Patent (No. 4139561) was entitled "Novel DNA Cloning Method" while the Mexican Patent (No. 252928) was entitled "Methods and compositions for directed cloning and subcloning using homologous recombination". Both patents broadly cover the major areas of Gene Bridges' RED/ET Recombination technology. This is the same technology that (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, announced that it has been granted patents in Japan and in Mexico relating to the Company s recombineering technology. The Japanese Patent (No. 4139561) was entitled "Novel DNA Cloning Method" while the Mexican Patent (No. 252928) was entitled Methods and compositions for directed cloning and subcloning using homologous recombination . Both patents broadly cover the major areas of Gene Bridges RED/ET (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, announced that it has been granted patents in Japan and in Mexico relating to the Company s recombineering technology. The Japanese Patent (No. 4139561) was entitled "Novel DNA Cloning Method" while the Mexican Patent (No. 252928) was entitled œMethods and compositions for directed cloning and subcloning using homologous recombination . Both patents broadly cover the major areas of Gene Bridges RED/ET (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=69 23 Apr 2008 - Gene Bridges GmbH announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial details were disclosed. Dr. Alan Berry, Director, Microbial Physiology and HTS at Novozymes Inc. in Davis, CA (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=69 02 Apr 2008 - Gene Bridges GmbH announced that Genencor International Inc. USA, a part of Danisco US Inc., has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Genencor for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial details were disclosed. Gary Stevens, CEO of Gene Bridges (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Genencor International Inc. USA, a part of Danisco US Inc., has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Genencor for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, today announced that Genencor International Inc. USA, a part of Danisco US Inc., has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, announced that Mbiotech will distribute Gene Bridges patented Red/ET recombination technology in Korea. Mbiotech was selected due to its expertise producing and marketing a wide range of molecular biology reagents. Under the terms of the agreement, Mbiotech will be the exclusive source of recombineering kits and reagents for the Korean the biotech community. Gary Stevens, CEO of Gene Bridges GmbH, added: We are (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, announced that Mbiotech will distribute Gene Bridges patented Red/ET recombination technology in Korea. Mbiotech was selected due to its expertise producing and marketing a wide range of molecular biology reagents. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, announced that it has been granted Korean Patent No. 10-0751587, entitled Methods and compositions for directed cloning and sub-cloning using homologous recombination by the Korean Patent Office. The patent broadly covers the major areas of Gene Bridges RED/ET recombineering technology. This is the same technology that is already covered by issued patents in the USA and EU. Gary Stevens, CEO of Gene Bridges (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=69 HEIDELBERG, Germany-(BUSINESS WIRE)-Gene Bridges GmbH, the recombineering company, announced that it has been granted Korean Patent No. 10-0751587, entitled "Methods and compositions for directed cloning and sub-cloning using homologous recombination" by the Korean Patent Office. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Development and refinement of methods to analyse differential gene expression has been essential in the progress of molecular biology. A novel approach called iGentifier is presented for profiling known and unknown transcriptomes, thus bypassing a major limitation in microarray analysis. The iGentifier technology combines elements of fragment display (e.g. Differential Display or RMDD) and tag sequencing (e.g. SAGE, MPSS) and allows for analysis of samples in high throughput using current (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 An operon consisting of three open reading frames, annotated in silico as methylmalonyl-CoA (mm-CoA) epimerase, mm-CoA mutase (MCM), and meaB, was identified in the sequencing project of the myxobacterium Sorangium cellulosum So ce56. This putative MCM pathway operon was subcloned from a bacterial artificial chromosome by Red/ET recombineering onto a minimal replicon derived from p15A. This plasmid was modified for integration and heterologous expression in Pseudomonas putida to enable the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Although many secondary metabolites exhibiting important pharmaceutical and agrochemical activities have been isolated from myxobacteria, most of these microorganisms remain difficult to handle genetically. To utilize their metabolic potential, heterologous expression methodologies are currently being developed. Here, the Red/ET recombination technology was used to perform all required gene cluster engineering steps in E. coli prior to the transfer into the chromosome of the heterologous host. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Recombineering is the use of homologous recombination in Escherichia coli for DNA engineering. Of several approaches, use of the lambda phage Red operon is emerging as the most reliable and flexible. The Red operon includes three components: Redalpha, a 5 to 3 exonuclease, Redbeta, an annealing protein, and Redgamma, an inhibitor of the major E. coli exonuclease and recombination complex, RecBCD. Most E. coli cloning hosts are recA deficient to eliminate recombination and therefore enhance the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Allelic variation at multiple genetic loci may contribute to hypertension. Since autonomic/sympathetic dysfunction may play an early, pathogenic, heritable role in hypertension, we evaluated candidate loci likely to contribute to such dysfunction, including catecholamine biosynthetic enzymes, catecholamine transporters, neuropeptides, and adrenergic receptors. Since chromosomal locations and physical map positions of many of these loci had not yet been identified, we used the GeneBridge4 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Glia from many diverse organisms play a number of important roles during the development of the nervous system. Therefore, knowing the molecules that control glial cell function will further our understanding of the mechanisms that control nervous system development. We have isolated a novel gene in Drosophila melanogaster that is expressed in a subset of the peripheral glia. We call this gene Fire exit (Fie), as the glia that express this gene do so during a time when they mark the entry and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 BACKGROUND: In cervical tumours the integration of human papilloma viruses (HPV) transcripts often results in the generation of transcripts that consist of hybrids of viral and cellular sequences. Mapping data using a variety of techniques has demonstrated that HPV integration occurred without obvious specificity into human genome. However, these techniques could not demonstrate whether integration resulted in the generation of transcripts encoding viral or viral-cellular sequences. The aim of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Sequence tagged sites generated for 60 NotI clones (NotI-STSs) from human chromosome 3-specific NotI-jumping and NotI-linking libraries were physically located using PCR screening of a radiation hybrid (RH) GeneBridge4 panel. The NotI map of chromosome 3 was generated using these RH-mapping data and those obtained earlier by FISH and sequencing of the corresponding NotI clones. The sequences of the NotI clones showed significant homologies with known genes and/or ESTs for 58 NotI-STSs (97%). (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 We report the characterization by genomics-based approach of the human H4-receptor gene structure. The H4-receptor gene have been mapped by radiation hybrid experiments (Gene Bridge 4) on chromosome 18q11.2, between the AFMBB11WH5 and CHLC.GATA85D10 markers. The H4-receptor gene spans more than 21 kbp and contains three exons separated by two large introns ( 7 kbp). RT-PCR analysis showed that the H4-receptor gene encoded a 3.7 kb mRNA which did not seem to be alternatively spliced within its (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Driven by the needs of functional genomics, DNA engineering by homologous recombination in Escherichia coli has emerged as a major addition to existing technologies. Two alternative approaches, RecA-dependent engineering and ET recombination, allow a wide variety of DNA modifications, including some which are virtually impossible by conventional methods. These approaches do not rely on the presence of suitable restriction sites and can be used to insert, delete or substitute DNA sequences at (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Hurpin (protease inhibitor 13; PI13) is the most recently identified member of the ovalbumin family of serine protease inhibitors (serpins). It is expressed in human epidermal keratinocytes and is downregulated by exposure to ultraviolet irradiation. A role for hurpin in the proliferation or differentiation of keratinocytes has been proposed because of its strong expression in proliferating cells and its deregulated expression in the lesional epidermis of psoriatic patients. Here, we report (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 The human CKAP2 gene, which is involved in diffuse large B-cell lymphomas, was localized via screening the GeneBridge 4 somatic cell radiation hybrid panel by means of the polymerase chain reaction (PCR). The CKAP2 gene was mapped between the WI-15460 and WI-3673 markers at the boundary between regions 13q14.3 and 13q21.1, at the distance of 14.39 cR (with 4.8 cR per cM) from the WI-5867 framework marker (lod score 2.26). The human CKAP2 gene displayed high homology to mouse and rat expressed (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Sliding between adjacent microtubules within the axonema gives rise to the motility of cilia and flagella. The driving force is produced by dynein complexes which are mainly composed of the axonemal dynein heavy chains. We used cells of human respiratory epithelium after in vitro ciliogenesis to clone cDNA fragments of nine dynein heavy chain genes, one of which had never been identified before. Dynein heavy chains are highly conserved from protozoa to human and the evolutionary ancestry of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 OBJECTIVE: The purpose of the present work is to establish the intron-exon organization from exon 12 to exon 23 of the human thyroglobulin gene and to construct a physical map of the 5 terminal half of the gene. DESIGN: Screening of a genomic library and subsequent restriction map, hybridization and sequencing methods have been employed to characterize the recombinant positive phages. METHODS: A human genomic DNA library was screened by in situ hybridization. Southern blotting experiments were (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Ten DNA markers were localized in the human genome by a screening procedure against the radiation hybrid somatic cell panel (GeneBridge 4 RH Panel) using polymerase chain reaction (RH mapping method). DNA markers were developed to nucleotide sequences adjacent to NotI sites of human chromosome 3 (NotI-STS markers) and also to nucleotide sequences of human cDNA (EST markers). Three EST markers mapped (B10164, S16R and 18F5R) were localized in the human genome for the first time. Marker B10164 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Historically, linkage mapping populations have consisted of large, randomly selected samples of progeny from a given pedigree or cell lines from a panel of radiation hybrids. We demonstrate that, to construct a map with high genome-wide marker density, it is neither necessary nor desirable to genotype all markers in every individual of a large mapping population. Instead, a reduced sample of individuals bearing complementary recombinational or radiation-induced breakpoints may be selected for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 Autosomal dominant hereditary spastic paraplegia (AD-HSP) is a genetically heterogeneous disorder characterized by progressive spasticity of the lower limbs. A major locus (SPG4) causing AD-HSP in about 40% of the families was mapped to chromosome 2p. The analysis of six SPG4-linked AD-HSP families using the RED procedure previously showed the expansion of a CAG repeat in affected individuals. To identify the gene responsible for this form of HSP, we have constructed a 3.5-Mb YAC contig (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 More than 100 genes causing inherited retinal diseases have been mapped to chromosomal locations, but less than half of these genes have been cloned. Mutations in many retina/pineal-specific genes are known to cause inherited retinal diseases. Examples include mutations in arrestin, rhodopsin kinase, and the cone-rod homeobox gene, CRX. To identify additional candidate genes for inherited retinal disorders, novel retina/pineal-expressed EST clusters were identified from the TIGR Human Gene (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 PURPOSE: The goal of this study was to develop efficient methods to identify tissue-specific expressed sequence tags (ESTs) and to map their locations in the human genome. Through a combination of database analysis and laboratory investigation, unique retina-specific ESTs were identified and mapped as candidate genes for inherited retinal diseases. METHODS: DNA sequences from retina-specific EST clusters were obtained from the TIGR Human Gene Index Database. Further processing of the EST (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 We have constructed a high-resolution map of a 6-Mb interval of human chromosome 5, band q31, incorporating 175 sequence tagged sites, of which 33 are genetic polymorphisms and 122 are nonredundant expressed sequences. The map was assembled initially as a YAC contig, incorporating data from radiation hybrid maps. To improve resolution and to identify errors in the databases, a radiation hybrid breakpoint map was developed for the interval, which included hybrids from both Stanford G3 and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 KET is a member of the newly discovered family of proteins that is related to the tumor suppressor p53. Here we describe the molecular cloning of a human cDNA of 4846 bp encoding a protein of 680 amino acids. The human KET protein shares 98% identity with the previously characterized rat homolog. The remarkably high degree of conservation lends support to the notion that KET proteins have important basic functions in development and differentiation. Using the GeneBridge 4 radiation hybrid (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 The mouse neurological mutant lethargic (lh) is characterized by ataxia, focal myoclonus, and absence epilepsy due to a loss-of-function mutation in the beta4 subunit of the voltage-gated calcium channel. To evaluate the role of this channel subunit in human neurological disease, we determined the chromosomal location and intron/exon structure of the human CACNB4 gene. The 1560-bp open reading frame of the CACNB4 cDNA predicts a 58-kDa protein with an amino acid sequence that is 99% identical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=69 By applying the recognition mask strategy to 300 mammalian sequences containing NotI sites we demonstrated that 5 ends of genes are highly enriched in NotI sites. A NotI linking clone NL2-252 (D3S1678) containing transferrin receptor (TFRC) gene was used as an initial point for chromosomal jumping. One of the jumping clones, J21-045 traverses 210 kbp and links NL2-252 to NL26 (D3S1632), a NotI linking clone containing highly polymorphic sequences. The TFRC gene was mapped to 3q29, close to the (…)